Kazandjian, D., Diamond, B., Hoffman, J., Pandey, A., Coffey, D., Kaddoura, M., Walker, B., Lessen, D., Diaz, C., Mompoint, S., Gutierrez, S., Chapman, J., Zhou, Y., Georgiou, M., Kuker, R., Koubek, K., Kowalski, A., Gallardo, L., Fernandes, S., Flores, F., Bukhari, R., Han, S., Armogan, M., Landgren, O. (2025). A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study). Blood. https://doi.org/10.1182/blood-2025-248